CelLBxHealth (FRA:DWV) ROE % Adjusted to Book Value: -3,043.29% (As of Dec. 2025)


What is CelLBxHealth ROE % Adjusted to Book Value?

CelLBxHealth FRA:DWV ROE % Adjusted to Book Value is -3,043.29% as of Dec. 2025. The stock has 5 warning signs investors should review.

CelLBxHealth's ROE % for the quarter that ended in Dec. 2025 was -213.03%. CelLBxHealth's PB Ratio for the quarter that ended in Dec. 2025 was 0.07. CelLBxHealth's ROE % Adjusted to Book Value for the quarter that ended in Dec. 2025 was -3,043.29%.

CelLBxHealth ROE % Adjusted to Book Value Related Terms

CelLBxHealth ROE % Adjusted to Book Value Historical Data

* Premium members only.

The historical data trend for CelLBxHealth's ROE % Adjusted to Book Value can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

CelLBxHealth ROE % Adjusted to Book Value Chart

CelLBxHealth Annual Data
Trend Apr16 Apr17 Apr18 Apr19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
ROE % Adjusted to Book Value
Get a 7-Day Free Trial Premium Member Only Premium Member Only -5.93 -17.20 -57.92 -50.91 -2,089.86

CelLBxHealth Semi-Annual Data
Apr16 Oct16 Apr17 Oct17 Apr18 Oct18 Apr19 Oct19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24 Jun25 Dec25
ROE % Adjusted to Book Value Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -67.44 -37.27 -44.49 -57.93 -3,043.29

FRA:DWV vs TMO, DHR, IDXX: ROE % Adjusted to Book Value Comparison

For the Diagnostics & Research subindustry, CelLBxHealth's ROE % Adjusted to Book Value, along with its competitors' market caps and ROE % Adjusted to Book Value data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

CelLBxHealth ROE % Adjusted to Book Value vs Medical Diagnostics & Research Industry

For the Medical Diagnostics & Research industry and Healthcare sector, CelLBxHealth's ROE % Adjusted to Book Value distribution charts can be found below:

* The bar in red indicates where CelLBxHealth's ROE % Adjusted to Book Value falls into.


CelLBxHealth ROE % Adjusted to Book Value Calculation

CelLBxHealth's ROE % Adjusted to Book Value for the fiscal year that ended in Dec. 2025 is calculated as

ROE % Adjusted to Book Value=ROE % / PB Ratio
=-146.29% / 0.07
=-2,089.86%

CelLBxHealth's ROE % Adjusted to Book Value for the quarter that ended in Dec. 2025 is calculated as

ROE % Adjusted to Book Value=ROE % / PB Ratio
=-213.03% / 0.07
=-3,043.29%

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

What does a ROE % Adjusted to Book Value of -3,043.29% mean?
CelLBxHealth (FRA:DWV) has a ROE % Adjusted to Book Value of -3,043.29% as of Dec. 2025. Return on equity adjusted to book is the ratio of return on equity to price-book ratio. View historical data on CelLBxHealth and its competitors.
Is CelLBxHealth's ROE % Adjusted to Book Value too high?
CelLBxHealth's current ROE % Adjusted to Book Value is -3,043.29%.
How does CelLBxHealth's ROE % Adjusted to Book Value compare to TMO and DHR?
CelLBxHealth's ROE % Adjusted to Book Value of -3,043.29% can be compared against companies in the Medical Diagnostics & Research industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good ROE % Adjusted to Book Value for a Medical Diagnostics & Research company?
A good ROE % Adjusted to Book Value depends on the Medical Diagnostics & Research industry context. However, ROE % Adjusted to Book Value should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high ROE % Adjusted to Book Value mean?
A high ROE % Adjusted to Book Value can signal that a stock is expensive relative to its fundamentals. Return on equity adjusted to book is the ratio of return on equity to price-book ratio. View historical data on CelLBxHealth and its competitors. CelLBxHealth's current ROE % Adjusted to Book Value is -3,043.29%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is CelLBxHealth stock overvalued right now?
Based on GuruFocus' analysis, CelLBxHealth (FRA:DWV) is currently considered Possible Value Trap. The stock's GF Value™ is €0.07, compared to a current price of €0.02 — trading 75.7% below its estimated fair value. The current ROE % Adjusted to Book Value is -3,043.29%. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is ROE % Adjusted to Book Value calculated?
ROE % Adjusted to Book Value is calculated from a company's financial statements. For CelLBxHealth (FRA:DWV), the current ROE % Adjusted to Book Value is -3,043.29% as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

CelLBxHealth Business Description

Other Exchanges ANPCF:USACLBX:UK
Address 10 Nugent Road, The Surrey Research Park, Surrey, Guildford, GBR, GU2 7AF
CelLBxHealth PLC is active in the healthcare sector in the United Kingdom. The Company's principal trading activity is undertaken in relation to the development and commercialization of the Parsortix cell separation system, with deployment in liquid biopsy that is non-invasive cancer diagnostics. It is a medical diagnostic company specializing in the development of pioneering products in cancer diagnostics. Its patented Parsortix technology can potentially treat and diagnose various forms of cancer. The Parsortix system can capture and harvest CTCs from patient blood. Its geographical segments include Europe and North America, of which the majority of its revenue is generated from Europe.